Plain-English translation of NCT07328373 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking for biological and genetic markers—like specific patterns in your blood or genes—that might predict whether someone with depression will relapse after stopping their antidepressant medication. Researchers will collect blood samples and health information from people with depression who have improved on treatment, as well as from healthy volunteers without a history of depression. The goal is to help doctors make better, more personalized decisions about when it's safe to discontinue medication.
Right now, doctors don't have clear guidelines for how long someone should stay on antidepressants, and about 40% of people experience depression returning after stopping the medication. While basic information like age or sex doesn't predict who will relapse, biological markers in the blood or genes might help identify who can safely stop treatment without increased risk.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may have blood samples taken to look for biological markers, answer questions about your depression history, and allow researchers to access your medical records. Some participants will be followed over time to see whether their depression returns after stopping medication, while others with known outcomes will participate at a single visit. The study involves approximately 204 participants and combines information collected both at single timepoints and over several months.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
Turkey (Türkiye)